General Information

We are an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. We launched the iStent, our first MIGS device, in the United States in July 2012 and we are leveraging our platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. We believe the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide.

Employees: 126
Founded: 1998
Contact Information
Address 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653, US
Phone Number (949) 367-9600
Web Address
View Prospectus: Glaukos
Financial Information
Market Cap $546.5mil
Revenues $52.0 mil (last 12 months)
Net Income $-9.1 mil (last 12 months)
IPO Profile
Symbol GKOS
Exchange NYSE
Shares (millions): 6.0
Price range $18.00 - $18.00
Est. $ Volume $108.0 mil
Manager / Joint Managers J.P. Morgan/ BofA Merrill Lynch/ Goldman Sachs
CO-Managers William Blair/ Cantor Fitzgerald
Expected To Trade: 6/25/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change